Michael Barbella, Managing Editor08.11.22
The U.S. Patent and Trademark Office has issued ENDRA Life Sciences Inc. its 28th patent .
U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation,” protects the TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad bandwidth, which reduces TAEUS’ sensitivity to tissue variation and temperature. The ‘272 patent will serve as the parent patent for future patent applications prosecuted in China and Europe.
“We are pleased with the issuance of our 28 th patent in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs,” ENDRA Chairman and CEO Francois Michelon said. “We continue to strengthen our intellectual property (IP) portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 48 patents issued globally.”
ENDRA Life Sciences developed Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to visualize tissue like MRI, but at 1/50 th the cost and at the point of patient care. TAEUS works in concert with more than 500,000 ultrasound systems currently in use globally. TAEUS is initially focused on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualizing tissue temperature during energy-based surgical procedures.
U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation,” protects the TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad bandwidth, which reduces TAEUS’ sensitivity to tissue variation and temperature. The ‘272 patent will serve as the parent patent for future patent applications prosecuted in China and Europe.
“We are pleased with the issuance of our 28 th patent in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs,” ENDRA Chairman and CEO Francois Michelon said. “We continue to strengthen our intellectual property (IP) portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 48 patents issued globally.”
ENDRA Life Sciences developed Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to visualize tissue like MRI, but at 1/50 th the cost and at the point of patient care. TAEUS works in concert with more than 500,000 ultrasound systems currently in use globally. TAEUS is initially focused on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualizing tissue temperature during energy-based surgical procedures.